FDA Brief

Warning letters Drugs

FDA warning letter to

Mane & Steel, LLC. dba Mane & Steel

LowIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.

What happened

FDA reviewed the website https://maneandsteel.com in August 2025 and found it offers compounded drug products, including semaglutide. FDA cited website claims such as 'Clinically Proven Weight Loss' and 'Clinically proven GLP-1 therapy' as false or misleading because compounded drugs are not FDA-approved, making the products misbranded (falsely or misleadingly labeled or promoted).

What FDA found

  1. The website's claim 'Clinically Proven Weight Loss' for compounded semaglutide was false or misleading because the product is not FDA-approved.

    FDCA section 502(a) [21 U.S.C. § 352(a)]
  2. The claim that the therapy is 'clinically proven' to suppress appetite, regulate blood sugar, and accelerate fat loss implied the compounded product was the same as an FDA-approved product.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. FDA said the advertising or promotion of the compounded semaglutide was false or misleading, which makes the compounded drug misbranded.

    FDCA section 502(bb) [21 U.S.C. § 352(bb)]
  4. The misbranded compounded semaglutide was introduced or delivered for introduction into interstate commerce.

    FDCA section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

Within 15 working days of receipt, send OCQC in CDER's Office of Compliance a written response describing specific steps taken to address the violations and prevent recurrence, with supporting documents. If you cannot finish within that time, state the reason and your planned timeline.

Who should pay attention

  • telehealth and online weight-loss drug sellers
  • compounders and pharmacies selling semaglutide
  • marketing teams making 'clinically proven' claims for compounded drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low